Aptose Presents Highlights from Clinical Update

Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML PatientsFavorable safety with monotherapy responses across four dose levels with no DLT in...

Related Keywords

Germany ,United States ,Toronto ,Ontario ,Canada ,Canadian ,Aptose Biosciences ,Susan Pietropaolo ,Aptose Biosciences Inc ,Lifesci Advisors ,European Hematology Association In Frankfurt ,Exchange Commission ,International Congress ,Finalized Dose ,Dose Exploration Trial ,European Hematology Association ,Chief Executive ,United States Securities ,Sci Advisors ,Nasdaq Apto ,Nc ,Pto ,Uspetinib ,Hematology ,Uxeptinib ,Pml ,Leukemia ,